RxDoctor Payments Data

Jill Brant

Nurse Practitioner · Johnstown, PANPI 1528474541

Payments from drug & device makers

$6,133in general payments, 2019–2025

Across 359 payments — averaging $17.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$669
  • AstraZeneca$601
  • Lilly USA, LLC$522
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$454
  • Amgen$280
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$6,06799%
  • Education$661%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,133 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$25,236
Medicare patients
150
Services billed
1,797

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban24$14,671
Soliqua 100-33Insulin Glargine/Lixisenatide12$12,732
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$10,110
Albuterol Sulfate HfaAlbuterol Sulfate68$1,549
Levothyroxine Sodium24$705
Doxycycline Monohydrate116$686
Tamsulosin Hcl18$639
Gabapentin52$632
Atorvastatin Calcium34$519
Metoprolol Succinate27$466
Losartan Potassium19$457
Sertraline Hcl22$430
Methylprednisolone58$382
Amlodipine Besylate48$373
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip13$368

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$116$14,67124 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$80$12,73212 claims
GSKTrelegy Ellipta$188$10,11014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Johnstown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →